Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos Therapeutics receives Nasdaq deficiency notice for late Q1 10-Q filing

Vivos Therapeutics, Inc.

Received Nasdaq deficiency on May 23, 2023 for not filing Q1 10-Q on time.
Failure due to recent auditor change from Plante & Moran to Moss Adams.
Company has until July 22, 2023 to submit a plan to regain compliance.
If plan accepted, Nasdaq may grant exception until November 20, 2023.
Company expects to file Q1 10-Q in coming weeks to resolve delinquency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

May 23, 2023, Vivos Therapeutics, Inc. (the “ Company ”) received a staff deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended March 31, 2023, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “ Periodic Filing Requirement ”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. The Company’s failure to file its Form 10-Q for the quarter ended March 31, 2023 is consider

View on SEC.gov

Browse all listing & compliance notices →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.